Hospital Acquired Pneumonia Drugs Market is Projected to Reach US$ 3.8 Billion by the End of 2020
Read Report Overview @ https://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
As per TMR, the global market for hospital acquired pneumonia drug is projected to reach US$ 3.8 bn by the end of 2020. North America is expected to lead the market during the forecast period. This is for the reason that the region witnesses a high incidence of pneumonia and hospital-acquired infections. The presence of large number of vendors has also made the North America market grow distinctively.
Patients who have undergone a surgery, are on enteral feeding, or are immunocompromised are more vulnerable to acquiring hospital acquired pneumonia. The hospital acquired pneumonia is also prevalent among the newborns, as they might suffer from respiratory syncytial virus (RSV) which has been identified as one of the major reason for nosocomial pneumonia.
The increasing incidence of hospital acquired pneumonia has pushed the government to take effective and strict measures that can address the root cause of these types of infections. Many programs have been implemented to minimize the cases related to hospital acquired pneumonia, but that will certainly minimize the need for hospital acquired pneumonia drugs in the overall market. One restraint may hinder the hospital acquired pneumonia drug market to grow during the forecast period.
Request for the Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881
The demand for hospital acquired pneumonia drug has increased mainly due to the unhealthy environment in hospitals and inadequate healthcare infrastructure in developing economies. The healthcare conditions in the growing economies are very low as per the international standards and lack in proper hygiene are leading to increasing healthcare associated diseases. The factors that create an unhealthy environment are often caused due to inadequate financial resources, poor infrastructure, and over-crowded hospitals that increase the chances of communicable diseases. In addition, inappropriate use of sanitary drugs and inadequate sanitary condition have increased the chances of development of MDR microorganism, the organism responsible for the rise of hospital acquired pneumonia.
The information presented in this review is based on a TMR report, titled “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Late Stage Candidates – (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix); Early Stage Candidates (Phase II, Phase I and Preclinical Trials - AR-101 or KBPA101, GSK 2189242A, BAL30072, MEDI4893, AR 301 or KBSA301, ME1100, V114, AR-104 or KBPA104, AR-201 or KBRV201, AR-401 or KBAB401) Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”.
Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hospital Acquired Pneumonia Drugs Market is Projected to Reach US$ 3.8 Billion by the End of 2020 here
News-ID: 1195883 • Views: 114
More Releases from Transparency Market Research
Powder Coatings Market to Reach US$ 16,203.14 Mn by 2026 Need for Increased Agri …
The demand within the global powder coatings market is slated to grow by leaps and bounds in the years to follow. The need for coating several materials and products with protective layers has played a vital role in the growth of the global powder coatings market. Request Overview - https://www.transparencymarketresearch.com/powder-coatings-market.html Furthermore, advancements in organic as well as polymer chemistry have paved way for key developments within the market. Several industrial manufacturers acknowledge
Fumigation Products Market to Reach a Value of US$ 1.2 Bn by 2027-Lack of Awaren …
Fumigation Products Market: Key Highlights The global fumigation products market was valued at ~US$ 820 Mn in 2018, and is anticipated to expand at a CAGR of ~4% during the forecast period. The global fumigation products market is driven by the rise in the demand for warehouses/storage and residential applications North America accounts for a major share of the global fumigation products market, led by an increase in the demand for residential housing,
Inks Market will Generate Revenue of US$ 21.2 Bn by 2027- Technological Advancem …
Global Inks Market: Key Highlights The global inks market was valued at ~US$ 15.9 Bn in 2018, and is anticipated to expand at a CAGR of ~3% from 2019 to 2027. Rise in population and urbanization is fueling global trade, and subsequently, the use of packaging. Online trade is further increasing the need for packaging. Products are also being consumed immediately, which is driving the need for food service packaging and
Zinc-Bromine Battery Market to Reach Value US$ 23 Mn by 2027 Enhancing Storage i …
The global zinc-bromine battery market was valued at ~US$ 5 Mn in 2018, and is anticipated to expand at a CAGR of ~18% from 2019 to 2027, according to a new research report published by Transparency Market Research (TMR). Increase in the demand for zinc-bromine batteries in power distribution applications is one of the major factors driving the zinc-bromine battery market. In terms of consumption, Asia Pacific accounted for a
More Releases for Pharma
Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business